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Objective To compare intramuscular oxytocin, Syntometrine and
carbetocin for prevention of postpartum haemorrhage after
vaginal birth.
Design Randomised double-blinded clinical trial.
Setting Six hospitals in England.
Population A total of 5929 normotensive women having a
singleton vaginal birth.
Methods Randomisation when birth was imminent.
Main outcome measures Primary: use of additional uterotonic
agents. Secondary: weighed blood loss, transfusion, manual
removal of placenta, adverse effects, quality of life.
Results Participants receiving additional uterotonics: 368 (19.5%)
oxytocin, 298 (15.6%) Syntometrine and 364 (19.1%) carbetocin.
When pairwise comparisons were made: women receiving
carbetocin were significantly more likely to receive additional
uterotonics than those receiving Syntometrine (odds ratio [OR]
1.28, 95% CI 1.08–1.51, P = 0.004); the difference between
carbetocin and oxytocin was non-significant (P = 0.78);
Participants receiving Syntometrine were significantly less likely to
receive additional uterotonics than those receiving oxytocin (OR
0.75, 95% CI 0.65–0.91, P = 0.002). Non-inferiority between
carbetocin and Syntometrine was not shown. Use of Syntometrine
reduced non-drug PPH treatments compared with oxytocin (OR
0.64, 95% CI 0.42–0.97) but not carbetocin (P = 0.64). Rates of
PPH and blood transfusion were not different. Syntometrine was
associated with an increase in maternal adverse effects and
reduced ability of the mother to bond with her baby.
Conclusions Non-inferiority of carbetocin to Syntometrine was
not shown. Carbetocin is not significantly different to oxytocin for
use of additional uterotonics. Use of Syntometrine reduced use of
additional uterotonics and need for non-drug PPH treatments
compared with oxytocin. Increased maternal adverse effects are a
disadvantage of Syntometrine.
Keywords Postpartum haemorrhage, prevention, uterotonic.
Tweetable abstract IM carbetocin does not reduce additional
uterotonic use compared with IM Syntometrine or oxytocin.
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Introduction
Postpartum haemorrhage (PPH) is the loss of ≥500 ml
blood from the genital tract after childbirth.1 PPH remains
the most common cause of direct maternal death globally,2
and is mostly related to uterine atony.3 Oxytocin, Syn-
tometrine (a fixed dose combination of oxytocin/er-
gometrine; Alliance Pharmaceuticals, Chippenham, UK)
and carbetocin are uterotonic agents employed to prevent
atony and PPH.Clinicaltrials.gov registration NCT02216383
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Oxytocin requires cold-chain storage,4 which can be dif-
ficult in low- and middle-income settings. Syntometrine is
the most commonly used uterotonic for PPH prevention in
some settings,5 even though its use is associated with
maternal hypertension, nausea and even maternal death.6
Carbetocin is now heat-stable but can be more expensive
than oxytocin.4
Recent robust studies have compared different uteroton-
ics7 and different oxytocin administration routes,8 and
there has been a network meta-analysis of different utero-
tonics.9 However, no clinical trial has directly compared
intramuscular oxytocin, Syntometrine and carbetocin for
prevention of PPH after vaginal birth, including quality of
life measurement.
Methods
Trial design, conduct and oversight
The IMox Study was a multicentre, double-blind ran-
domised active-controlled trial comparing intramuscular
oxytocin, Syntometrine and carbetocin for the prevention
of primary postpartum haemorrhage after vaginal birth.
Participants were randomised to three parallel arms.10
The trial was approved by the South Central–Oxford B
Research Ethics Committee, the Medicines and Healthcare
products Regulatory Agency and the Health Research
Authority in the UK with oversight by North Bristol NHS
Trust Research and Innovation Department.
An external Data Monitoring Committee (DMC) pro-
vided independent oversight and an independent statistician
provided a blinded report to the DMC partway through
recruitment, focusing on data quality, recruitment, safety
and completeness of databases. There were no pre-specified
stopping guidelines. Study end-date was the time when
sample size was reached for the number of randomised par-
ticipants providing primary outcome data. Ferring Pharma-
ceuticals funded the trial medication and blinding.
Aims
The primary study aims were to determine whether:
 Intramuscular (IM) carbetocin is as effective as IM Syn-
tometrine
 IM carbetocin is more effective than IM oxytocin
 IM Syntometrine is more effective than IM oxytocin
For the primary outcome measure, a non-inferiority
comparison was made between carbetocin and Syn-
tometrine because fewer maternal adverse effects may make
carbetocin a better option. Superiority comparisons were
made between carbetocin and oxytocin, and Syntometrine
and oxytocin.
The secondary study aims were to determine whether:
 Carbetocin is associated with fewer adverse effects than
Syntometrine and oxytocin
 Choice of uterotonic agent affects maternal quality of life
in the first two postnatal weeks
Trial participants
Women planning a vaginal birth were recruited from six
maternity units from two regions in England. Start dates
were staggered by 2 months.
Women aged 18 years or more with a spontaneous or
assisted vaginal birth of a live singleton baby at ≥24 weeks
of gestation were eligible. Patient Information Leaflets were
provided to all pregnant women when attending an anom-
aly ultrasound scan at a recruiting site during the study
period. Stickers on the front of maternity notes indicated
who had received a leaflet. Anyone missed was opportunis-
tically given a leaflet at subsequent visits. Women were
recruited and consented in the antenatal period. When
approached, women were given the time they felt necessary
to consider their options. Women were not approached
where there was any distress that may compromise capac-
ity. Women were not eligible for recruitment once they
were in established labour (≥4 cm cervical dilatation).
Exclusion criteria included hypertension, antepartum
haemorrhage, suspected placental abruption, maternal
coagulation disorder, women who would decline blood
products, epilepsy, and contraindication to any of the study
drugs. All participants provided written consent.
Randomisation, allocation and blinding
A computer-generated drug allocation sequence was created
by an independent statistician, with an assignment ratio of
1:1:1 and block size of nine, stratified by site. All three
uterotonics were provided in identical 1-ml ampoules con-
taining 1 ml of uterotonic. Ampoules were blinded by use
of snapper tops and opaque labels, with boxes labelled
according to the allocation sequence (see Supplementary
material, Figure S1). The carbetocin used was not the heat-
stable formulation, as this was not available at study onset.
Heat-stable carbetocin varies from the non-heat-stable for-
mulation only in its excipients.7 All study drugs were
stored in refrigerators. Women were randomised when
vaginal birth was imminent with assignment to the next
consecutively numbered box by the midwife caring for the
participant. All clinical staff (outcome assessors), research-
ers and participants remained blinded until data lock after
study closure.
Interventions
A single intramuscular injection of the allocated uterotonic
(10 IU oxytocin, 500 µg/5 IU Syntometrine or 100 µg car-
betocin) was administered immediately after clamping of
the umbilical cord, and before expulsion of the placenta.
The intervention was withheld if the participant was no
longer eligible after randomisation (e.g. emergency
2 ª 2021 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd
van der Nelson et al.
caesarean section or hypertension), or if consent was with-
drawn. Once there was no further concern about ongoing
bleeding following delivery of the placenta, blood and
blood-soaked materials were collected and weighed using
digital scales. Dry weights were subtracted to measure
blood loss. Blood pressure was measured at 1 and 2 hours
postdelivery.
Participants completed a maternal adverse effects ques-
tionnaire at 2 hours postdelivery, and an EQ-5D-5L health-
related quality of life questionnaire on days 1 and 14 post-
delivery. Women recruited before commencement of the
latent phase of labour also completed an antenatal EQ-5D-
5L questionnaire. Trial participation ended at the 14-day
postnatal follow up.
Primary and secondary outcomes
The primary outcome measure was the proportion of
women receiving additional uterotonics after administra-
tion of the study drug.10 Staff were briefed, in training ses-
sions, to administer additional uterotonics only when the
uterus was inadequately contracted, with ongoing vaginal
bleeding.
Secondary outcome measures included: weighed blood
loss (ml), duration of third stage of labour, transfusion of
blood products, use of other ‘non-drug’ measures to treat
PPH (examination under anaesthetic/intrauterine balloon/
uterine compression suture/interventional radiology) and
maternal blood pressure at 1 and 2 hours postdelivery.
Participant-reported outcomes (by questionnaire at
2 hours postdelivery) included nausea, vomiting, headache,
dizziness, abdominal pain, and whether these symptoms
adversely affected their ability to bond with/care for their
baby in the first two postnatal hours. The question relating
to ability to bond was binary (yes/no). Health utility scores
were calculated from EQ-5D-5L questionnaires antenatally,
and on days 1 and 14 postdelivery.
Other data for PPH risk factors1 were also collected,
including mode of birth, ethnicity, pyrexia in labour and
length of labour, to allow for adjustment of the results and
analysis.10
The trial protocol was first registered on Clinicaltrials.-
gov in August 2014 and recruitment commenced in Febru-
ary 2015. The DMC reported in October 2017. The trial
completed in October 2018. One of the recommendations
of the DMC was the clarification of timescales relating to
some outcomes. In response to this, outcome definitions
were clarified in the protocol and online at clinicaltrials.gov
in July 2018. Neither the outcomes themselves nor their
collection method were changed. Epilepsy was added as an
exclusion criteria 3 months into trial recruitment in
response to the listing of epilepsy as a contraindication to
the use of carbetocin in the Summary of Product Charac-
teristics. This was approved by the Medicines and
Healthcare products Regulatory Agency and Research
Ethics Committee.
A Core Outcome Set for trials investigating postpartum
haemorrhage was published after our study had finished
recruiting.11
Patient involvement
A Maternity Service User Panel contributed to the study
design, and reviewed the recruitment process, Patient
Information Leaflet and maternal adverse effects question-
naire early in trial development, to optimise participant
experience and relevance. Positive feedback was received
about the inclusion of maternal bonding data. Changes
instigated included midwives reading postnatal question-
naires out loud if participants did not wish to read at
2 hours postdelivery.
Sample size
The sample size calculation was based on weighted (for
study size) mean prevalence, estimated by pooling of prior
available data for the primary outcometaken from studies
of intramuscular uterotonic drugs after vaginal birth:12–17
use of additional uterotonics of 19.1% oxytocin, 15.2%
Syntometrine and 11.5% carbetocin.
Sample size was chosen to ensure equal sample sizes
across pairwise comparisons, and for the non-inferiority
comparison and the two superiority comparisons to have
>80% power. Assuming a non-inferiority margin of 1 and
95% power for the comparison between carbetocin and
Syntometrine, 1904 participants were required per arm.
Using the same number of participants in the oxytocin
arm (total sample size of 5712), a four-point difference
between oxytocin and Syntometrine could be detected with
88% power (a = 0.05), and an eight-point difference
between oxytocin and carbetocin with 99% power
(a = 0.05).
Attrition between randomisation (birth imminent) and
administration of the study uterotonic (immediately after
birth) was initially predicted to be 10%, and the sample
size was inflated to 6285 participants in early protocols.
When actual attrition was found to be less than 0.5%, this
inflation was removed, and the required sample remained
at 5712.
Statistical analysis
The intention-to-treat (ITT) population includes all partici-
pants randomised. Those that received a study drug form
the modified ITT population (mITT). Some participants
did not receive the Interventional Medicinal Product that
they were originally assigned to. In the mITT analyses,
these participants were analysed according to their original
randomisation. In the Per Protocol (PP) analyses, they were
analysed according to the uterotonic received.
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We present the primary outcome results reported by
randomised arm for the mITT population. In supplemen-
tary analyses, we report results PP (see Supplementary
material, Tables S1–S5). Sensitivity analysis used the ITT
population.
For the primary outcome we used an omnibus test for
difference in proportions receiving additional uterotonic
drugs, using the chi-square test of association. Statistical
significance was two-sided P < 0.05. The chi-square test of
association was used to examine superiority of Syn-
tometrine versus oxytocin, and carbetocin versus oxytocin,
with sample proportions as point estimates and the Pear-
son chi-square method to create confidence intervals for
differences in proportions. The non-inferiority margin
described in the original study protocol was further clari-
fied on the recommendation of the Data Monitoring Com-
mittee after study commencement. The non-inferiority
margin is 1 percentage point, as detailed in the protocol
publication.10 In the comparison between carbetocin and
Syntometrine, non-inferiority was declared if the upper
limit of the two-sided 95% CI for the proportion receiving
additional uterotonics was less than the non-inferiority
margin of 1 percentage point.
A Bonferroni adjustment was also made using a two-
sided 98.3% confidence interval, to account for a three-way
comparison. Both sets of confidence intervals are presented
for the primary outcome data.
Analyses for all secondary outcomes were conducted only
for superiority, using an appropriate omnibus test. The sec-
ondary outcome ‘weighed estimated blood loss (ml)’ was cate-
gorised (<500 ml, ≥500 ml, ≥1000 ml, ≥2000 ml) for analysis.
Secondary outcomes were not adjusted for multiplicity.
An a priori designated sensitivity analysis was performed
using the ITT group. Missing primary outcome data were sub-
stituted with an assumption that the rate of additional utero-
tonic drugs required was any value between 10 and 25%,
covering any rate likely to be encountered in clinical practice.
The primary outcome was adjusted for known PPH risk
factors including induction of labour, body mass index and
previous PPH using multivariable logistic regression.1 The
same was done for the outcome of PPH ≥500 ml.
Health states generated from the EQ-5D-5L were valued
from the EQ-5D-3L preference utility weights for the UK
population using Van Hout’s crosswalk method.18 All anal-




A total of 5929 women were recruited and randomised
from six maternity units between February 2015 and
August 2018 (Figure 1); of these, 212 became ineligible
after randomisation and did not receive a study drug and
5717 received a study drug and were included in the mITT
analyses.
Fifty-one participants (15 oxytocin, 16 Syntometrine, 14
carbetocin) did not receive the drug they were first ran-
domised to (Figure 1); randomisation occurred when birth
was believed imminent, but the uterotonic was then dis-
carded after a longer than anticipated second stage of
labour (the blinded Interventional Medicinal Product
required ‘immediate’ administration, as per the Summary
of Product Characteristics of non-heat-stable carbetocin.)
For these participants, the next consecutively numbered
uterotonic was administered. Thirty-four participants (10
oxytocin, 14 Syntometrine, 14 carbetocin) were involved in
a protocol breach (Figure 1). The remaining 5638 partici-
pants were included in the PP analyses. Maternal character-
istics at baseline and characteristics of babies at birth were
similar between the three groups (Table 1).
Primary outcome
In the mITT population, primary outcome data were miss-
ing for four participants (0.2%) in the oxytocin arm and
two participants (0.1%) in the carbetocin and Syntometrine
arms (Table 2).
The use of additional uterotonics differed by 3.54 per-
centage points between the carbetocin and Syntometrine
arms (95% CI 1.14–5.93%). With our pre-specified non-in-
feriority margin of 1%, non-inferiority of carbetocin to
Syntometrine was therefore not shown, as the upper limit
of the confidence interval is >+1 (see Supplementary mate-
rial, Figure S2). Women in the carbetocin arm were more
likely to receive additional uterotonics than those in the
Syntometrine arm (odds ratio [OR] 1.28, 95% CI 1.08–
1.51, P = 0.004).
There was a very small, non-significant difference of
0.36% in the use of additional uterotonic drugs between
the oxytocin and carbetocin arms (95% CI 2.87 to
2.15%). Women in the carbetocin arm were no more likely
to receive additional uterotonic drugs than those in the
oxytocin arm (OR 0.98, 95% CI 0.83–1.15, P = 0.78).
There was a 3.90% difference in use of additional utero-
tonics between the Syntometrine and oxytocin arms (95%
CI 6.31 to 1.49%). Women randomised to Syn-
tometrine were less likely to receive additional uterotonics
than those randomised to oxytocin (OR 0.75, 95% CI
0.65–0.91, P = 0.002). Bonferroni correction did not affect
the conclusions.
In a sensitivity analysis, we included the primary out-
come data for all women in the ITT analysis but excluded
from the mITT analyses and PP analyses. The data were
systematically imputed with an assumed need for additional
uterotonic drugs in the range of 12–25%. Over all of these
combinations, the same overarching conclusion was of no
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Figure 1. CONSORT diagram showing flow of participants through The IMox Study. *Uterotonic that participants originally randomised to discarded
as out of fridge too long (birth believed to be imminent when randomised but took longer). Next consecutively numbered drug administered. APH,
antepartum haemorrhage; BP, blood pressure.
Table 1. Baseline characteristics (modified Intention-To-Treat population)
Characteristic Oxytocin (n = 1894) Syntometrine (n = 1914) Carbetocin (n = 1909)
Median age, years (IQR) 30 (26–33) 30 (26–34) 30 (26–34)
Median BMI, kg/m2 (IQR) 25 (22–30) 25 (22–30) 25 (22–30)
Parity
Nulliparous, n (%) 814 (42.9) 852 (44.6) 780 (40.9)
Parity 1–4, n (%) 1061 (56.0) 1032 (54.0) 1095 (57.3)
Parity 5+, n (%) 20 (1.1) 25 (1.4) 33 (1.8)
History of previous PPH, n (% of parous women) 155 (14.3) 127 (12.0) 147 (13.0)
Median gestational age at birth, completed weeks (IQR) 39 (38–41) 39 (38–40) 40 (38–41)
Onset of labour induced, n (%) 1339 (70.7) 1340 (70.3) 1391 (73.1)
Median birthweight (kg) (IQR) 3.43 (3.08–3.77) 3.42 (3.07–3.77) 3.44 (3.11–3.79)
Mode of birth
Spontaneous, n (%) 1492 (78.8) 1453 (76.2) 1486 (78.0)
Instrumental, n (%) 401 (21.2) 454 (23.8) 420 (22.0)
Baseline antenatal utility score from EQ-5D 0.81 0.81 0.81
Asian ethnicity, n (%) 66 (3.5) 60 (3.2) 66 (3.5)
Intrapartum characteristics (used in Table S4)
Prolonged labour, n (%) 244 (12.9) 256 (13.4) 219 (11.5)
Pyrexia in labour, n (%) 66 (3.5) 89 (4.7) 76 (4.0)
Spontaneous birth, n (%) 1492 (79.8) 1453 (76.2) 1486 (78.0)
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significant difference between oxytocin and carbetocin, and
the percentage receiving an additional uterotonic drug was
consistently significantly lower in the Syntometrine arm
compared with carbetocin or oxytocin.
In the logistic regression model (see Supplementary
material, Table S4), women randomised to carbetocin or
oxytocin remained significantly more likely to receive addi-
tional uterotonic drugs than those randomised to Syn-
tometrine after adjusting for risk factors and recruiting site.
As per protocol, multiple imputation using chained equa-
tions was performed, but this did not alter any conclu-
sions.







Missing data for outcome
Primary outcome
Need for additional uterotonics (mITT population) 368 (19.5%) 298 (15.6%) 364 (19.1%) 8 participants (4 oxytocin, 2
syntometrine 2 carbetocin)






7 participants (4 oxytocin, 1
syntometrine, 2 carbetocin)
Secondary outcomes (mITT)
Median blood loss (ml), (IQR) 500 (290–834) 483 (288–820) 500 (298–837) Data for weighed blood loss was
missing for 8 participants (0
oxytocin, 3 syntometrine, 5
carbetocin)
Weighed blood loss ≥500 ml 949 (50.5%) 920 (48.2%) 961 (50.4%)
Weighed blood loss ≥1000 ml 355 (18.7%) 352 (18.4%) 330 (17.3%)
Weighed blood loss ≥2000 ml 74 (3.9%) 59 (3.1%) 56 (2.9%)
Duration of third stage of labour (minutes), (IQR) 10 (7–14) 9 (6–14) 10 (7–14)
Blood transfusion 58 (3.1%) 51 (2.7%) 54 (2.8%) 4 participants (2 syntometrine, 2
carbetocin)
Manual removal of placenta 43 (2.3%) 49 (2.6%) 57 (3.0%) 4 participants (1 oxytocin, 3
syntometrine, 1 carbetocin)
Other surgical/mechanical (‘non-drug’) methods to
treat PPHa
58 (3.1%) 38 (2.0%) 42 (2.2%) 6 participants (1 oxytocin, 2
syntometrine, 3 carbetocin)
Blood pressure: hypertension in first 2 postnatal
hoursb
134 (7.1%) 233 (12.3%) 132 (7.0%) 21 participants (1 oxytocin, 10
syntometrine, 10 carbetocin)
Blood pressure: hypotension in first 2 postnatal
hoursc
47 (2.5%) 30 (1.6%) 31 (1.6%)
Nausea 169 (8.9%) 458 (24.0%) 153 (8.0%) Maternal adverse effects not
completed for 3 participants (0
oxytocin, 2 syntometrine, 1
carbetocin)
Vomitingd 92 (4.9%) 337 (17.6%) 91 (4.8%)
Headache 26 (1.4%) 65 (3.4%) 28 (1.5%)
Dizziness 163 (8.6%) 188 (9.8%) 123 (6.4%)
Abdominal pain 129 (6.8%) 162 (8.5%) 99 (5.2%)
Answer ‘yes’ to question ‘Have any of the above
symptoms affected your ability to bond with and/or
care for your baby in these first few hours?’
83 (4.4%) 160 (8.4%) 56 (2.9%) 188 participants (64 oxytocin, 63
syntometrine, 61 carbetocin)
Mean EQ-5D utility score: all returned antenatal
questionnaires
0.8107 0.8104 0.8115 638 participants (217 oxytocin, 210
syntometrine, 211 carbetocin)
Mean EQ-5D utility score: all returned day 1
postdelivery questionnaires
0.7553 0.7470 0.7578 359 participants (135 oxytocin, 113
syntometrine, 111 carbetocin)
Mean EQ-5D utility score: all returned day 14
postdelivery questionnaires
0.9031 0.8910 0.8998 783 participants (264 oxytocin, 262
syntometrine, 257 carbetocin)
Mean EQ-5D utility score for participants with a







1544 participants did not have a
complete EQ-5D dataset (528
oxytocin, 513 syntometrine, 503
carbetocin)
aComposite outcome of examination under anaesthetic/intrauterine balloon/uterine compression suture/interventional radiology.
bDefined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg in the first two postnatal hours.
cDefined as diastolic blood pressure < 90 mmHg in the first two postnatal hours.
dVomiting in those not already vomiting in labour.
e‘Complete’ defined as those participants who returned EQ-5D questionnaires antenatally, on day 1 and on day 14.
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95% CI 6.31 to 1.49
Bonferroni corrected 98.3%
CI 6.84 to 0.96




95% CI 2.87 to 2.15
Bonferroni corrected 98.3%
CI 3.42 to 2.69
OR 0.98, 95% CI 0.83–1.15,
P = 0.78
Primary outcome (PP population) Percentage difference 3.51%
95% CI 1.19 to 5.21
Bonferroni corrected 98.3%
CI 0.06–6.44




95% CI 6.14 to 1.28
Bonferroni corrected 98.3%
CI 6.66 to 0.70




95% CI 2.73 to 2.32
Bonferroni corrected 98.3%
CI 3.27 to 2.87
OR 0.99, 95% CI 0.84–1.16,
P = 0.89
Secondary outcomes
Weighed blood loss ≥500 ml P = 0.16, OR 1.10, 95% CI
0.96–1.24
P = 0.25, OR 0.93, 95% CI
0.82–1.05
P = 0.80, OR 1.02, 95% CI
0.90–1.15
Weighed blood loss ≥1000 ml P = 0.37, OR 0.93, 95% CI
0.79–1.09
P = 0.82, OR 0.91, 95% CI
0.83–1.16
P = 0.26, OR 0.91, 95% CI
0.77–1.07
Weighed blood loss ≥2000 ml P = 0.79, OR 0.95, 95% CI
0.66–1.38
P = 0.17, OR 0.78, 95% CI
0.55–1.11
P = 0.10, OR 0.75, 95% CI
0.52–1.06
Duration of third stage of labour P = 0.573, Mda 0, 95% CI 0,
0
P = 0.096, Mda 0, 95% CI
1, 0
P = 0.269, Mda 0, 95% CI
1, 0
Blood transfusion P = 0.76, OR 1.06, 95% CI
0.72–1.57
P = 0.52, OR 0.87, 95% CI
0.59–1.27
P = 0.68, OR 0.92, 95% CI
0.63–1.35
Manual removal of placenta P = 0.43, OR 1.17, 95% CI
0.79–1.72
P = 0.36, OR 1.14, 95% CI
0.75–1.72
P = 0.17, OR 1.33, 95% CI
0.89–1.98
Other surgical/mechanical (‘non-
drug’) methods to treat PPH
P = 0.64, OR 1.11, 95% CI
0.71–1.72
P = 0.04, OR 0.64, 95% CI
0.42–0.97
P = 0.10, OR 0.71, 95% CI
0.48–1.06
Hypertension in first two postnatal
hours
P < 0.001, OR 0.53, 95% CI
0.42–0.66
P < 0.001, OR 1.85, 95% CI
1.48–2.32
P = 0.88, OR 0.98, 95% CI
0.76–1.26
Hypotension in first two postnatal
hours
P = 0.91, OR 0.97, 95% CI
0.59–1.60
P = 0.83, OR 0.67, 95% CI
0.43–1.06
P = 0.07, OR 0.65, 95% CI
0.41 – 1.03
Nausea P < 0.001, OR 0.28, 95% CI
0.23–0.34
P < 0.001, OR 3.22, 95% CI
2.67–3.90
P = 0.32, OR 0.89, 95% CI
0.71–1.12
Vomiting P < 0.001, OR 0.23, 95% CI
0.18–0.30
P < 0.001, OR 4.20, 95% CI
3.30–5.35
P = 0.91, OR 0.98, 95% CI
0.73–1.32
Headache P < 0.001, OR 0.42, 95% CI
0.27–0.66
P < 0.001, OR 2.53, 95% CI
1.60–4.02
P = 0.80, OR 1.07, 95% CI
0.63–1.83
Dizziness P < 0.001, OR 0.63, 95% CI
0.50–0.80
P = 0.18, OR 1.16, 95% CI
0.93–1.45
P = 0.01, OR 0.73, 95% CI
0.57–0.93
Abdominal pain P < 0.001, OR 0.59, 95% CI
0.46–0.76
P = 0.05, OR 1.27, 95% CI
1.00–1.62
P = 0.04, OR 0.75, 95% CI
0.57–0.98
Answer ‘yes’ to question ‘Have any
of the above symptoms affected
your ability to bond with and/or
care for your baby in these first
few hours?’
P < 0.001, OR 0.33, 95% CI
0.24–0.45
P < 0.001, OR 2.00, 95% CI
1.52–2.62
P = 0.02, OR 0.66, 95% CI
0.47–0.93
aMd = difference of medians (continuous data).
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Secondary outcomes and adverse effects
There is no evidence of differences in the distribution of
blood loss volume (≥500 ml, ≥1000 ml, ≥2000 ml) between
all arms or any pairwise comparisons (Table 3). Duration
of the third stage of labour and rates of blood transfusion
were not different between groups, and mean transfusion
rate was 2.9% (see Supplementary material, Table S5 for
additional transfusion data).
Group allocation did not affect the rate of manual
removal of placenta, but use of Syntometrine did signifi-
cantly reduce the rate of ‘non-drug’ PPH treatment meth-
ods, but only when compared with oxytocin (2.0% versus
3.1%, OR 0.64, 95% CI 0.42–0.97).
Carbetocin and oxytocin were associated with less hyper-
tension in the first two postnatal hours than Syntometrine
(carbetocin versus Syntometrine OR 0.53, 95% CI 0.42–
0.66; Syntometrine versus oxytocin OR 1.85, 95% CI 1.48–
2.32).
Randomisation had no effect on hypotension rates
(Tables 2 and 3). Maternally reported adverse effects dif-
fered between groups (Table 2). Nausea, vomiting, abdomi-
nal pain and headache were less commonly associated with
carbetocin and oxytocin than Syntometrine. Syntometrine
and oxytocin caused more dizziness and abdominal pain
than carbetocin.
Participants receiving carbetocin or oxytocin were less
likely to report a reduced ability to bond with or care for
their baby in the first two postnatal hours than those
receiving Syntometrine (OR 0.33, 95% CI 0.24–0.45 for
carbetocin versus Syntometrine, and OR 2.00, 95% CI
1.52–2.62 for Syntometrine versus oxytocin).
Health-related quality of life
EQ-5D-5L questionnaire responses were available from
5079 (89%) participants antenatally, 5358 (94%) on day 1
postdelivery and 4923 (86%) on day 14 postdelivery. A
total of 4173 participants (73%) completed the question-
naire at all three time-points. Mean utility scores were no
different between groups at all time-points; utility scores
fell at day 1 compared with baseline scores and improved
above antenatal scores by day 14. Scores at 14 days for all
available data and for patients who completed the EQ-5D
at all three time-points were similar, suggesting any missing
data were at random.
Serious adverse events
A PPH ≥2000 ml was reportable as a serious adverse event
and accounted for 89% (177/198) of all events. The distri-
bution of the causes of the remaining 21 serious adverse
events was not different across arms and was not directly
attributable to the study drugs. No maternal deaths
occurred, and no hysterectomies were performed.
Discussion
Main findings
Intramuscular carbetocin or oxytocin resulted in more
additional uterotonic use than IM Syntometrine. Syn-
tometrine reduced the need for non-drug PPH treatments
compared with oxytocin. There was no difference in mea-
sured blood loss between groups but there were increased
maternal adverse effects with Syntometrine compared with
both oxytocin and carbetocin. The increase in adverse
effects with Syntometrine use explains the reduction in
maternally reported ability to bond with and care for her
baby in the first 2 hours. Maternal health-related quality of
life in the first two postnatal weeks was not different
between the uterotonics.
Strengths and limitations
This trial reports the results of the first direct comparison
of the three most commonly employed IM uterotonics for
prevention of PPH at vaginal birth. The large size, multi-
centre involvement and broad eligibility criteria of this
study support its external validity. The involvement of a
Maternity Service User Panel strengthened development of
the study protocol. This trial provides data for future anal-
yses of the cost-effectiveness of these agents, which is a
WHO priority.4 The 89–95% response rate for EQ-5D-5L
questionnaires was high.
Women with known or suspected hypertensive disorders
were excluded from this study, which may limit the general-
isability of our results to whole populations. There was a rel-
atively high proportion of participants whose labour was
induced because our study was hospital-based; women
attending hospital for antenatal assessment are more likely to
be induced,19 and those who are in hospital or undergoing
induction are more easily approached for participation. At
71.4%, the proportion of women with an induced labour
was higher than the background UK rate (32.6%).20 Regres-
sion analysis (see Supplementary material, Table S4) did
demonstrate a positive association between induction of
labour and both PPH ≥500 ml (OR 1.22, P = 0.002) and the
use of additional uterotonics (OR 1.40, P = 0.002). A core
outcome set for studies evaluating interventions for prevent-
ing PPH was published after our study had completed.11
Three of ten outcomes (shock, transfer for higher level of
care and breastfeeding) have not been reported in our study.
Interpretation
The PPH event rate in our study is higher than reported in
other recent studies.5,7,8 PPH ≥500 ml was approximately
three-fold higher than in the CHAMPION study7 and two-
fold higher than in the intramuscular oxytocin arm of a
recent randomised trial in Dublin.8 This is unlikely to be a
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result of differences in the timing of administration because
timing of cord clamping does not increase PPH risk.21 The
high rate of induced labours in our study may be con-
tributing, because induction is associated with increased
rates of PPH;22 the induction of labour rate was lower in
both the CHAMPION study (~14%)7 and the Dublin study
(53.1%).8 Further to this, the rate of instrumental vaginal
births in our study was ~21–24%, compared with ~4% in
CHAMPION. Instrumental vaginal birth is an important
risk factor for PPH,23 and complex births may be under-
represented in trials used to estimate PPH incidence.24
There is insufficient evidence to support one method of
blood loss estimation over another,25 including acceptabil-
ity to women. We made efforts to exclude liquor and com-
bined volumetric and gravimetric measurement of blood
loss by using direct collection of blood along with weighing
blood-soaked swabs and linen, excluding dry weights. It is
possible that our weighed blood loss might be increased by
inadvertent liquor contamination. It is also possible that
previously accepted incidence of 5–10% may underestimate
the true burden of PPH, particularly now that weighed esti-
mation is more common in routine clinical practice; the
incidence of PPH ≥500 ml for all maternities in Wales in
2017 was 34.0%,26 and was 57.7% after vaginal birth in
one Chinese centre in 2018.27
There could have been under-reporting in other studies:
despite a three-fold difference in PPH rate between this
study and CHAMPION,7 the rate of blood transfusion in
IMox was only twice that of the CHAMPION study (mean
2.9% versus 1.45%). The reported transfusion rate in the
CHAMPION study is the same as the reported blood loss
>1000 ml. Prevalent antenatal anaemia in developing coun-
tries may go some way to account for this. The transfusion
rate in this study is similar to a previous randomised trial
of carbetocin versus oxytocin at caesarean section in the
same healthcare region, published in 2010.28
The recent CHAMPION Study7 also did not identify any
significant difference between carbetocin and oxytocin for
use of additional uterotonics or maternal adverse effects.
The CHAMPION Study concluded that there was non-infe-
riority of carbetocin for PPH ≥500 ml at a margin of 1.16,
but there was no significant difference for PPH ≥1000 ml.
Our study results corroborate those of the Cochrane net-
work meta-analysis29 that concluded Syntometrine use does
not reduce PPH ≥1000 ml compared with oxytocin and
there are higher rates of adverse outcomes. Our study also
corroborates the network meta-analysis findings that Syn-
tometrine may reduce the use of additional uterotonics,
although the certainty of the evidence in the network
meta-analysis was low.9 However, our data do not support
the network meta-analysis conclusions that Syntometrine
and carbetocin probably reduce PPH ≥500 ml compared
with oxytocin. Mode of administration may be more
important than previously thought. Standard UK practice
for vaginal birth is IM administration, but the Dublin
study identified that there was a significant benefit to intra-
venous administration of oxytocin.8 The pharmacokinetics
of carbetocin demonstrate higher peak levels after intra-
venous administration compared with intramuscular,30
which may account for the benefits of intravenous carbe-
tocin identified at caesarean section.31 More research is
required to investigate routes of uterotonic administration
as well as parallel work to develop tools to prospectively
identify women who would benefit from intravenous
administration. Finally, we will use our data to investigate
the cost-effectiveness of the uterotonics employed in this
study.
Conclusion
This large multicentre randomised controlled trial demon-
strated that the use of IM Syntometrine during the third
stage of labour reduced the use of additional uterotonic
agents compared with both IM oxytocin and carbetocin,
and reduced the use of non-drug PPH treatments com-
pared with oxytocin. However, PPH and transfusion rates
were not different between the assigned uterotonics. Syn-
tometrine use resulted in more frequent maternal adverse
effects and compromised a mother’s ability to bond with
and care for her baby. There were no differences in day 1
and day 14 quality of life scores between the three utero-
tonics.
Our findings inform choices for prevention of PPH at
vaginal birth for clinicians, policy-makers and women. The
adverse effects of Syntometrine are an important disadvan-
tage in terms of safety and maternal birth experience and
must be weighed up against the benefit of reduced require-
ment for additional uterotonics. Moreover, Syntometrine
requires secure cold-chain storage and it is not widely
available or used in many settings globally.32
Oxytocin and carbetocin appear to be equally acceptable
to women and efficacious when used intramuscularly. Our
data support the WHO recommendation that both oxy-
tocin and carbetocin are appropriate drugs for PPH pre-
vention where their costs are comparable.
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